Evaluation and review of pharmacoeconomic models

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 9, 2004, Pages 1867-1880

  Hay, Joel W ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Cost benefit analysis; Cost effectiveness analysis; Decision modelling; Economic evaluations; Pharmacoeconomic guidelines

Indexed keywords

DRUG;

CLINICAL TRIAL; ECONOMIC EVALUATION; HUMAN; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; MEDICAL LITERATURE; MODEL; PARAMETER; PEER REVIEW; PUBLICATION; RETROSPECTIVE STUDY; REVIEW; TREATMENT WITHDRAWAL; VALIDATION PROCESS;

COST-BENEFIT ANALYSIS; DECISION TREES; ECONOMICS, PHARMACEUTICAL; MARKOV CHAINS; MODELS, ECONOMIC; MONTE CARLO METHOD; QUALITY-ADJUSTED LIFE YEARS; REPRODUCIBILITY OF RESULTS; UNCERTAINTY;

EID: 4544342750     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.9.1867     Document Type: Review

References (89)

1. LENS M, DAWES M: Economic evaluation in evidence based practice. Expert Opin. Pharmacother. (2002) 3(9):1239-1243.
2. Canadian Coordinating Office of Health Technology Assessment: Guidelines for Economic Evaluation of Pharmaceuticals: Canada (2nd edn). CCOHTA Publications, Ottawa, Canada (1997).
3. KANAVOS P, TRUEMAN P, BOSILEVAC A: Can economic evaluation guidelines improve efficiency in resource allocation? The cases of Portugal, The Netherlands, Finland, and the United Kingdom. Int. J. Technol. Assess. Health Care (2000) 16:1179-1192.
4. SULLIVAN SD, LYLES A, LUCE B, GRIGAR J: AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in US health plans and pharmacy benefits management organizations. J. Manag. Care Pharm. (2001) 7(4):272-282.
5. OLSON BM, ARMSTRONG EP, GRIZZLE AJ, NICHTER MA: Industry's perception of presenting pharmacoeconomic models to managed care organizations. J. Manag. Care Pharm. (2003) 9(2):159-167.
6. ELIXHAUSER A, HALPERN M, SCHMIER J, LUCE B: Health Care CBA and CEA from 1991 to 1996: an updated bibliography. Medical Care (1998) 36(5 Suppl. 1):MS1-MS9.
7. ISPOR Ninth Annual International Meeting Contributed Presentation Abstracts. Value Health (2004) 7(3):219-393.
8. KIELHORN A, GRAF VON DER SCHULENBURG J-M: The Health Economics Handbook. Adis International, Chester, UK (2000).
9. KLARMAN HE, FRANCIS JO, ROSENTHAL GD: Efficient treatment of patients with kidney failure. Medical Care (1968) 6:48-54.
10. Principles of Pharmacoeconomics. Bootman JL, Townsend RJ, McGhan WF (Eds), Whitney Books Co., Cincinnati, OH, USA (1991).
11. BUXTON MJ, DRUMMOND M, VAN HOUT BA et al.: Modelling In economic evaluation: an unavoidable fact of life. Health Economics (1997) 6:217-227.
12. HAY J, JACKSON J: Methodological issues in conducting pharmacoeconomic evaluations-modeling studies. Value Health (1999) 2(3):78-81.
13. CLAXTON K: The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. J. Health Econ. (1999) 18:341-364.
14. HAY J: Econometric issues in modeling the costs of AIDS. Health Policy (1989) 11(2):125-145.
15. HAY J, WOLAK F: A procedure for estimating the unconditional HIV infection distribution and its variability. J. R. Stat. Soc. Ser. C. Appl. Stat. (1994) 43(4):599-624.
16. BLOWER S, DOWLATABADI H: Sensitivity and uncertainty analysis of complex models of disease transmission: an HIV model as an example. Intl. Stat. Rev. (1994) 62(2):229-243.
17. BARR J, SCHUMACHER G: Decision analysis and pharmacoeconomics. In: Principles of Pharmacoeconomics (2nd edn). Bootman JL, Townsend RJ, McGhan WF (Eds), Whitney Books Co., Cincinnati, OH, USA (1996).
18. CHEN L, HAY J: Cost-effectiveness of implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc. Drugs Ther. (2004) 18(2):161-170.
19. BRIGGS A, SCULPHER M: An introduction to Markov modeling for economic evaluation. Pharmacoeconomics (1998) 13(4):397-409.
20. HAY J, WITTELS E, GOTTO A: An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am. J. Cardiol. (1991) 67:789-796.
21. ETEMAD L, HAY J: Cost effectiveness analysis of pharmaceutical care in a Medicare drug benefit program. Value Health (2003) 6(4):425-435.
22. KARNON J: Alternative decision modelling techniques for the evaluation of health care technologies: Markov processes versus discrete event simulation. Health Econ. (2003) 12:837-848.
23. LAW AM, KELTON WD: Simulation Modeling and Analysis (3rd edn). McGraw-Hill Higher Education, Boston, MA, USA (2000).
24. HUNINK M, GLASZIOU P, SIEGEL J et al.: Decision Making in Health and Medicine. Integrating Evidence and Values. Cambridge University Press, Cambridge, UK (2001).
25. OBENCHAIN R, MELFI C, CROGHAN T, BUESCHING D: Bootstap analyses of cost effectiveness in antidepressant pharmacotherapy. Pharmcoeconomics (1997) 11:464-472.
26. DOUBILET P, BEGG CB, WEINSTEIN MC, BRAUN P, MCNEIL BJ: Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med. Decis. Making (1985) 5(2):157-177.
27. GOLD M, SIEGEL J, RUSSELL L, WEINSTEIN M: Cost-Effectiveness in Health and Medicine. Oxford University Press, New York, NY, USA (1996).
28. AVORN J: Benefit and cost analysis in geriatric care: turning age discrimination into health policy. N. Engl. J. Med. (1984) 310:1294-1301.
29. KRUPNICK AJ: Valuing Health Outcomes: Policy Choices and Technical Issues. Resources for the Future Report. Washington DC (2004).
30. WAGSTAFF A: QALYs and the equity-efficiency trade-off. J. Health Econ. (1991) 10:21-41.
31. JOHANNESSON M: The relationship between cost-effectiveness analysis and cost-benefit analysis. Social Science and Medicine (1995) 41:483-489.
32. BLEICHRODT H, QUIGGIN J: Life cycle preferences over consumption and health: when is cost-effectiveness analysis equivalent to cost - benefit analysis? J. Health Econ. (1999) 18:681-708.
33. MELTZER D: Accounting for future costs in medical cost-effectiveness analysis. J. Health Econ. (1997) 16:33-64.
34. GARBER AM, PHELPS CE: Economic foundations of cost effectiveness analysis. J. Health Econ. (1997) 16:1-31.
35. KLOSE T: A utility-theoretic model for QALYs and willingness to pay. Health Econ. (2003) 12:17-31.
36. JOHANNESSON M, KARLSSON G: The friction cost method: a comment. J. Health Exon. (1997) 16:249-255.
37. KOOPMANSCHAP MA, RUTTEN FFH, VAN INEVELD BM, VAN ROIJEN L: The friction cost method for estimating the indirect costs of disease. J. Health Econ. (1995) 14:171-189.
38. DEVLIN N, PARKIN P: Does Nice Have a Cost Effectiveness Threshold and What Other Factors Influence its Decisions: a Discrete Choice Analysis. Dept of Economics Discussion Paper Series 03/01, City University of London, London, UK (2003).
39. LOUVIERE J, HENSHER D, SWAIT J: Stated Choice Methods. Cambridge University Press, New York, NY, USA (2000).
40. BINGHAM M, JOHNSON FR, MILLER D: Modeling choice behavior for new pharmaceutical products. Value Health (2001) 4(1):1-13.
41. HAY J: Conjoint analysis in pharmaceutical research. J. Manag. Care Pharm. (2002) 8(3):206-209.
42. LLOYD AJ: Threats to the estimation of benefit: are preference elicitation methods accurate? Health Econ. (2003) 12:393-402.
43. Choices, Values and Frames. Kahneman D, Tversky A (Eds). Cambridge University Press, New York, NY, USA (2000).
44. LAZARO A: Theoretical arguments for the discounting of health consequences where do we go from here? Pharmacoeconomics (2002) 20(14):943-961.
45. GRAVELLE H, SMITH D: Discounting for health effects in cost benefit and cost effectiveness analysis. Health Econ. (2001) 10(7):587-599.
46. WEINSTEIN M, STASON W: Foundations of cost-effectiveness analysis for health and medical practices. N. Engl. J. Med. (1977) 296:716-721.
47. HAY J, ERNST R, MEISSNER C: Respiratory syncytial virus immune globulin: a cost effectiveness analysis. Am. J. Manag. Care (1996) 2(2):851-861.
48. NATIONAL INSTITUTE FOR CLINICAL EXCELLENCE: Guide to the Methods of Technology Appraisal. London, UK (2004).
49. Methods for Meta-Analysis in Medical Research. Sutton AJ, Abrams KR, Jones DR et al. (Eds), Wiley Series in Probability and Statistics, New York, NY, USA (2000).
50. GORDIS L: Epidemiology. WB Saunders Company, New York, NY, USA (1996).
51. RITTENHOUSE B, O'BRIEN B: Threats to the validity of pharmacoeconomic analyses based on clinical trial data. In: Quality of Life and Pharmacoeconomics in Clinical Trials (2nd edn). Spilker B (Ed.), Lippincott-Raven Publishers, Philadelphia, PA, USA (1996).
52. EVANS C, CRAWFORD B: Data collection methods in prospective economic evaluations: how accurate are the results? Value Health (2000) 3(4):277-286.
53. MOTHERAL B, BROOKS J, CLARK M et al.: A checklist for retrospective database studies: report of the ISPOR task force on retrospective databases. Value Health (2003) 6(2):90-97.
54. TERZA J: Estimating endogenous treatment effects in retrospective data analysis. Value Health (1999) 2(6):429-434.
55. HAY J: Health care costs and outcomes: how should we evaluate real world data? Value Health (1999) 2(6):417-420.
56. WOOLDRIDGE J: Econometric Analysis of Cross Section and Panel Data. MIT Press, Cambridge, MA, USA (2002).
57. OISHI S, MORTON S, MOORE A: Using data to enhance the expert panel process: Rating indications of alcohol-related problems in older adults. Int. J. Technol. Assess. Health Care (2001) 17(1):125-136.
58. LUCE B, SHIH YCT, CLAXTON K: Introduction: Bayesian approach to technology assessment and decision making. Int. J. Technol. Assess. Health Care (2001) 17(1):1-5.
59. WINKLER RL: Why Bayesian analysis hasn't caught on in healthcare decision making. Int. J. Technol. Assess. Health Care (2001) 17(1):56-66.
60. BRIGGS AH, FENN P: Confidence intervals or surfaces? Uncertainty on the cost-effectiveness plane. Health Econ. (1998) 7:723-740.
61. BRIGGS AH: Handling uncertainty in cost-effectiveness models. Pharmacoeconomics (2000) 17(5):479-500.
62. DOUBILET P, BEGG CB, WEINSTEIN MC, BRAUN P, MCNEIL BJ: Probabilistic sensitivity analysis using Monte Carlo simulation. A practical approach. Med. Decis. Making (1985) 5(2):157-177.
63. OBENCHAIN RL: Resampling and multiplicity in cost-effectiveness inference. J. Biopharm. Stat. (1999) 9(4):563-582.
64. HAY J: Economic models and sensitivity analysis. Value Health (1998) 1(3):187-193.
65. BECK JR, PAUKER SG, KASSIRER JP: A convenient approach of life expectancy: Part I. Validation of the method. Am. J. Med. (1982) 73:884-888.
66. BECK JR, PAUKER SG, GOTTLIEB JE, KLEIN K, KASSIRER JP: A convenient approach of life expectancy: Part II. Use in medical decision-making. Am. J. Med. (1982) 73:889-897.
67. GUYATT G, DRUMMOND M, FEENY D et al.: Guidelines for the clinical and economic evaluation of health care technologies. Soc. Sci. Med. (1986) 22:393-408.
68. Economic analysis of health care technology. A report on principles. Task Force on Principles for Economic Analysis of Health Care Technology. Ann. Intern. Med. (1995) 123:61-70.
69. CLEMENS K, TOWNSEND R, LUSCOMBE F et al.: Methodological and conduct principles for pharmacoeconomic research. Pharmaceutical Research and Manufacturers of America. Pharmacoeconomics (1995) 8:169-174.
70. MENON D, SCHUBERT F, TORRANCE GW: Canada's new guidelines for the economic evaluation of pharmaceuticals. Med. Care (1996) 34(12 Suppl.):DS77-DS86.
71. DRUMMOND MF, JEFFERSON TO: Guidelines for authors and peer reviewers of economic submissions to the BMJ. Br. Med. J. (1996) 313:275-283.
72. WEINSTEIN MC, SIEGEL JE, GOLD MR et al.: Recommendations of the panel on cost-effectiveness in health and medicine. JAMA (1996) 276:1253-1258.
73. ALBAN A, GYLDMARK M, PEDERSEN AV et al.: The Danish approach to standards for economic evaluation methodologies. Pharmacoeconomics (1997) 12:627-636.
74. WEINSTEIN M, O'BRIEN B, HORNBERGER J et al.: Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on Good Research Practices - Modeling Studies. Value Health (2003) 6:9-17.
75. CHIOU C-F, HAY J, WALLACE J et al.: Development and validation of a grading system for the quality of cost-effectiveness studies. Med. Care (2003) 41:32-44.
76. OFMAN J, SULLIVAN S, NEUMANN P, CHIOU C-F, HENNING J, HAY J: Examining the value and quality of health economic analyses: implications of utilizing the QHES. J. Manag. Care Pharm. (2003) 9(1):53-62.
77. YU YF, HAY JW,YU AP: Cost-effectiveness of long-term hormone replacement therapy (estrogen plus progestin) in healthy postmenopausal women for osteoporosis prevention. ISPOR Conference Abstract POS4. Value Health (2004) 7(3):296-297.
78. HAY J: Evaluating the cost-effectiveness of statins. J. Manag. Care Pharm. (2004) 10(1):569-571.
79. HENKE CJ, BURCHMORE MJ: The economic impact of tacrine in the treatment of Alzheimer's disease. Clin. Therapeut. (1997) 19:330-345.
80. LUBECK DP, MAZONSON PD, BOWE T: The potential impact of tacrine on expenditures for Alzheimer's disease. Med. Interface (1995) 7:130-138.
81. WIMO A, KARLSSON G, NORDBERG A, WINBLAD B: Treatment of Alzheimer's disease with tacrine - a cost analysis model. Alzheimer Dis. Assoc. Disord. (1997) 11:191-200.
82. O'BRIEN B, GOEREE R, HUX M et al.: Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada. Am. Geriatr. Soc. (1999) 47(5):570-578.
83. AD2000 COLLABORATIVE GROUP: Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): randomised double-blind trial. Lancet (2004) 363:2105-2115.
84. CLEGG A, BRYANT J, NICHOLSON T et al.: Clinical and cost effectiveness of donepezil, rivastigmine and galantamine for Alzheimer's disease. The National Institute for Clinical Excellence, London, UK (2000).
85. HAY J, ZAMMIT D: Alzheimer survival and nursing home free survival: Cognition, behavior and comorbities. International Psychogeriatric Association 11th International Congress, Chicago, IL, USA (2003) (Abstract 2361).
86. CLAXTON K, NEUMANN PJ, ARAKI S, WEINSTEIN MC: Bayesian value-of-information analysis: An application to a policy model of Alzheimer's disease. Int. J. Technol. Assess. Health Care (2001) 17(1):38-55.
87. NEUMANN PJ, HERMANN RC, KUNTZ KM et al.: Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease. Neurology (1999) 52:1138-1145.
88. KASSIRER JP, ANGELL M: The journal policy on cost-effectiveness analysis. N. Engl. J. Med. (1994) 331:669-670.
89. MOSCARELLI M, RUPP A: J. Ment. Health Policy Econ. (1998) 1:105-107 (Editorial).